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Doxorubicin is an anthracycline antibiotic with potent antineoplastic properties ef-
fective against a broad spectrum of malignancies such as non-Hodgkin’s lymphoma,
acute lymphoblastic leukaemia, breast carcinoma and several other types of cancers. The
mechanism of cytotoxicity involves specific intercalation of the planar anthracycline nu-
cleus of doxorubicin to the DNA double helix, resulting in prevention of further DNA
replication (1). One of the major drawbacks in chemotherapy with doxorubicin is its car-
diotoxicity (2). Pharmaceutical scientists have made several attempts to improve the the-
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A rapid and sensitive high performance liquid chroma-
tographic (HPLC) assay utilizing fluorimetric detection
(excitation at 480 nm, emission at 560 nm) for the deter-
mination of doxorubicin in dog blood was developed and
validated. Treatment of blood samples containing doxo-
rubicin with AgNO3 (as protein precipitant) resulted in
appearance of an additional peak in the chromatogram
of doxorubicin at 11.5 min along with the parent peak (tR
= 5.5 min). The latter peak was not found when treated
with other protein precipitants such as trichloroacetic acid
and methanol. Construction of a calibration curve based
on the area of the first peak alone did not result in linear-
ity of the curve. However, summation of areas of both
peaks resulted in a curve with good linearity and coeffi-
cient of determination (R2 = 0.9985). Appearance of the
second peak may be due to the interaction of doxorubi-
cin with cellular components of blood in the presence of
AgNO3 leading to the formation of a complex with redu-
ced polarity. Analysis of the quality control samples sho-
wed good accuracy (96.7–100.42) and precision (RSD =
2.6–5.7%). The proposed method could be advantageous
in estimation of doxorubicin incorporated into targeted
delivery systems that concentrate in blood cells and quan-
tify the absolute blood concentration of doxorubicin.
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rapeutic index of doxorubicin and overcome its adverse effects. As a result, a variety of
drug delivery systems containing doxorubicin were developed, such as microspheres,
liposomes, nanoparticles, antibodies and polyaminoacids.
Several methods were previously reported for quantification of doxorubicin in bio-
logical fluids and tissues. Techniques such as radioimmunoassay for determination of
doxorubicin in plasma and urine (3), voltammetry for urine (4, 5), high performance liq-
uid chromatography (HPLC) for rat lymph and gall (6), rat plasma and tissues (7), rat
serum, tissues (8) and bile (9), human plasma of cancer patients (10) and in blood (11),
and spectrofluorimetry for rabbit serum (12) and rat whole blood, plasma and tissues
(13) were used. Many of the above mentioned HPLC methods used extraction proce-
dures involving organic solvents such as chloroform or dichloromethane. Such proce-
dures are cumbersome and involve risks of incomplete drug extraction, loss of drug dur-
ing the transfer of contents and also high volatility of the solvent used for extraction.
Hence, a simple HPLC method, which avoids the above risk factors, would be advanta-
geous for rapid determination of doxorubicin in biological samples.
All the above mentioned HPLC techniques were used to determine doxorubicin
concentrations in plasma, serum or lymph. No method was reported for whole blood,
which includes combined estimation in plasma and blood cells.
As doxorubicin is a cytotoxic agent, there is a great possibility of its accumulation in
blood cells, especially when the drug is incorporated or bound to targeted delivery sys-
tems such as nanoparticles or liposomes. Under these conditions, estimation of doxo-
rubicin in plasma alone may result in underestimation of drugs circulating in the blood.
Hence, estimation of doxorubicin in whole blood may be meaningful since it provides a
true picture of the drug concentration in plasma as well as in blood cells.
In the present investigation, an attempt was made to develop a simple, rapid and
sensitive HPLC method for the estimation of doxorubicin in dog blood, and relevant an-
alytical parameters were established.
EXPERIMENTAL
Chemicals and reagents
Doxorubicin hydrochloride (DH) was a gift sample from RPG Life Sciences (India).
HPLC grade methanol and acetonitrile were purchased from J. T. Baker (USA).
All other chemicals and reagents used in the study were of analytical grade. Water
used for analysis was purified through the MilliQ water system (Millipore, USA).
Animals
Blood samples were collected from three male Mongrel dogs weighing 18–20 kg.
The dogs were housed in an animal cage and were fasted overnight before the collection
of blood samples. The dogs had access to water ad libitum. The dogs were cared and the
blood was collected as per the ethical standards of the institution.
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Standard solutions of doxorubicin
An accurate amount of doxorubicin hydrochloride was weighed in order to prepare
1 mg mL–1 stock standard solution in methanol. The stock solution was stored at 5 °C
when not in use.
Mobile phase
The buffer, pH 4.0, was prepared from 10 mmol L–1 ammonium hydrogen phos-
phate solution, to which 5 mL trimethyl amine was added. The pH of the solution was
adjusted to 4.0 with orthophosphoric acid.
The mobile phase was a mixture of buffer pH 4.0/acetonitrile/methanol (60:24:16,
V/V/V), sonicated for 10 min (Toshniwal ultrasonic cleaner, India) and filtered through
0.22 µm filter.
Reagents
Aqueous silver nitrate solution (30% m/V) was prepared by dissolving silver nitrate
in purified water. 100 µL of the reagent was used as protein precipitant.
Aqueous trichloroacetic acid (TCA) (10% m/V) was prepared by dissolving trichlo-
roacetic acid in purified water. 100 µL of the reagent was used as protein precipitant.
DNA solution (1 mg mL–1) was prepared by dissolving Salmon sperm DNA as mo-
del DNA (Hi-Media, India) in purified water. 100 µL of the reagent was used for the in-
teraction studies.
Instrumentation
The HPLC system (Waters, Milford, USA) used in this study consists of a Waters
2690 separations module (comprising a pump, a refrigerated auto sampler with a 100 µL
loop) and a Shimadzu RF-10 AXL fluorescence detector (Shimadzu Corporation, Japan).
The detector was set at 480 nm and 560 nm (excitation and emission wavelengths, re-
spectively). The detector was set at gain 3 and sensitivity 1. Chromatographic separation
was performed on a 150 x 4.6 mm i.d. reversed-phase column (Inertsil ODS-2, GL Sci-
ences, Japan) of 5 µ particle size. Separation of analytes was performed at a flow rate of
1.3 mL–1 min–1, and typical back pressure was 12.67 MPa.
Blood samples
Standard solution of doxorubicin hydrochloride (DH) was added to 400 µL dog
whole blood (containing EDTA) in a glass tube in respective amounts to obtain the final
concentrations of 5, 10, 40, 80, 160, 240 and 480 ng mL–1 of DH. To this mixtures 100 µL
of 30% AgNO3 was added. The contents were vortexed for 1 min and 5 mL methanol
was added. The mixture was extracted (Cole multipulse vortexer, Glas-Col, USA) for 10
min and centrifuged at 2000 rpm for 10 min at 20 °C. The supernatant was decanted into
another glass tube and evaporated to dryness at 60 °C under a stream of nitrogen. The
dried residue was reconstituted with 200 µL methanol and centrifuged at 15000 rpm for
10 min. Clear supernatant was collected in HPLC vials and loaded onto the HPLC system.
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Plasma used in the study was isolated from the whole blood containing EDTA by
centrifugation (Sigma 3K30 refrigerated High speed centrifuge, Sigma Instruments, Ger-
many) at 3000 rpm for 5 min.
Method validation
During method validation, LOD and LLOQ values and linearity were established from
the chromatograms based on three separate runs of freshly prepared calibration standards.
LOD and LLOQ were determined upon signal-to-noise approach, by comparing measured
signals from samples with known low concentrations of analyte with those of blank sam-
ples and by establishing the minimum concentration at which the analyte can be reliably
quantified with precision. The analyte response at the LOD should be at least 3 times and at
the LLOQ it should be at least 5 times the response compared to the blank response.
Accuracy of the method was tested by subjecting known amounts of doxorubicin to
recovery studies in six replicates in whole blood.
Stability
Stability of doxorubicin in dog whole blood samples was determined at two different
temperatures. DH was incubated in dog whole blood at concentrations of 75, 150 and
225 ng mL–1 at 5 °C for different time intervals ranging from 0 to 8 h, and at room tem-
perature (28 °C) for up to 3 days and assayed. Determinations were made in triplicate.
Results and discussion
A rapid and sensitive HPLC method was developed for the estimation of doxoru-
bicin in dog blood, which avoids extraction with non polar organic solvents such as
chloroform, dichloromethane (DCM), etc. Doxorubicin is a basic molecule (pKa = 8.22)
(1), and for better extraction into organic solvents such as chloroform or DCM, the sam-
ple pH should be adjusted to alkaline range (pH > 8.0). But, doxorubicin is unstable at
alkaline conditions (at about pH 9.0 it shows an indicator-like effect) (1). Unlike the re-
ported methods which used pH 9.2 borate buffer for extraction of doxorubicin into or-
ganic solvents (11, 14), in the present method, the pH of the buffer used for mobile phase
preparation was adjusted to 4.0, and hence can avoid the pH-dependent degradation
problems. As doxorubicin is a cytotoxic agent, after administration into the body, it could
be expected to penetrate and concentrate in blood cells. Hence its determination in plasma
or serum alone by neglecting the blood cells may lead to underestimation of the concen-
tration. Estimation in whole blood becomes important when the drug is incorporated
into delivery systems for purposes such as controlled and targeted delivery, since the
delivery system may concentrate in cells rather than circulate in plasma. Hence a new
method was developed for the determination of doxorubicin in dog whole blood.
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LOD =
concentration of injected sample x 3
S/N ratio of the injected sample
LLOQ =
concentration of injected sample x 5
S/N ratio of the injected sample
Figs. 1a–c show typical chromatograms of the doxorubicin standard retention time of
5.5 min, dog blank blood extract and doxorubicin-spiked blood extract. No interfering peaks
appeared in the chromatogram of the blood extract at the retention time of doxorubicin.
Protein precipitation of blood samples was carried out by addition of aqueous AgNO3
solution (Fig. 2a). Interestingly, this process resulted in appearance of a second peak
with retention time of 11.5 min in the chromatogram of the blood sample spiked with
doxorubicin.
To understand the cause of the appearance of the second peak in the chromatogram
of doxorubicin, a series of experiments with various permutations and combinations, in-
volving the influence of DNA (model DNA) and various protein precipitants were car-
ried out and the results are recorded in Table I. The second peak (tR = 11.5 min) did not
appear in the chromatogram of doxorubicin when the protein precipitation of blood con-
taining doxorubicin was carried out using other reagents such as TCA (Fig. 2b) and
methanol. It was hypothesized that the intercalating nature of doxorubicin with cellular
DNA might have resulted in a complex with reduced polarity, appearing as the second
peak. However, the chromatograms of the model systems of doxorubicin incubated with
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Fig. 1. HPLC chromatogram of: a) doxorubicin
standard (in methanol), b) dog whole blood,
c) doxorubicin spiked into dog blood.
a) b)
c)
AgNO3 solution in the presence or in the absence of DNA did not result in the second
peak, proving that neither AgNO3 nor DNA alone is responsible for the appearance of
the second peak, under in vitro conditions.
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Table I. Appearance of doxorubicin in dog whole blood and plasma samples
Sample composition tR1 (min) tR2 (min)
Doxorubicin solution (Fig. 1a) 5.5 –
DNA solution – –
AgNO3
a – –
Doxorubicin + DNA 5.5 –
Doxorubicin + AgNO3
a 5.5 –
Whole blood + AgNO3
a – –
Whole blood + trichloroacetic acidb – –
Whole blood + methanol – –
Whole blood + doxorubicin (Fig. 1c) 5.5 –
Whole blood + doxorubicin + AgNO3
a (Fig. 2a) 5.5 11.5
Whole blood + doxorubicin + trichloroacetic acidb (Fig. 2b) 5.5 –
Whole blood + doxorubicin + methanol 5.5 –
Plasma + doxorubicin + AgNO3
a (Fig. 3a) 5.5 –
Haemolyzed plasma + doxorubicin + AgNO3
a 5.5 11.5
Plasma + doxorubicin + trichloroacetic acidb (Fig. 3b) 5.8 –
Plasma + doxorubicin + methanol (Fig. 3c) 5.5 –
a 30% aqueous solution
b 10% aqueous solution
Fig. 2. Chromatogram of doxorubicin spiked into dog blood and treated with a protein
precipitant: a) AgNO3, b) trichloroacetic acid.
a) b)
Experiments were also conducted in dog plasma to check the appearance of the sec-
ond peak. Plasma samples with or without doxorubicin were prepared in a similar way
to that of whole blood samples, using three different protein precipitants, i.e., AgNO3,
TCA and methanol. Unlike the whole blood samples, the chromatograms of plasma
samples containing doxorubicin did not show the presence of the second peak (tR = 11.5
min) with any of the above protein precipitants (Fig. 3). In order to check whether the
second peak appears only in the presence of blood components, the doxorubicin was
spiked into slightly haemolyzed plasma and treated individually with the mentioned
three protein precipitants and subjected for HPLC. Interestingly, the second peak ap-
peared in the chromatograms of haemolyzed plasma samples treated with AgNO3 solu-
tion. A similar case could also be expected with tissues when AgNO3 is used as protein
precipitant. This strongly suggests that the second peak is due to the interaction of do-
xorubicin with cellular components in the presence of AgNO3 solution. Hence this fact
has to be noted and caution has to be exercised while using silver nitrate as protein pre-
cipitant for the treatment of whole blood or haemolyzed plasma samples in the estima-
tion of doxorubicin in biological samples.
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a) b)
Fig. 3. Chromatogram of doxorubicin
spiked into dog plasma treated with
a protein precipitant: a) 30% AgNO3,
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1 74.15 ± 7.73 (98.9)
2 71.75 ± 8.76 (95.7)
3 72.68 ± 7.76 (96.9)
150
1 148.59 ± 13.72 (99.1)
2 146.89 ± 13.65 (97.9)
3 143.80 ± 11.10 (95.9)
225
1 222.66 ± 14.34 (99.0)
2 225.83 ± 12.74 (100.4)
3 221.50 ± 13.62 (98.4)
28 Time (h)
75
0 72.34 ± 8.25 (96.5)
4 73.37 ± 9.04 (97.8)
8 72.18 ± 9.04 (96.2)
150
0 147.54 ± 12.35 (98.4)
4 149.87 ± 12.04 (99.9)
8 147.18 ± 12.04 (98.1)
225
0 221.63 ± 10.31 (98.5)
4 222.04 ± 12.07 (98.7)
8 224.08 ± 12.07 (99.6)
a Confidence interval at p = 0.05.
b n = 3 replicates.
c Recovery indicated in brackets.









75 72.55 ± 4.37 96.7 5.7
150 146.07 ± 6.60 97.4 4.3
225 225.86 ± 6.21 100.4 2.6
a CI – Confidence interval at p = 0.05.
b n = 6 replicates.
Construction of a calibration curve of doxorubicin in dog blood treated with AgNO3
as protein precipitant, and consideration of the area of the first peak alone (tR = 5.5 min)
did not result in a linear curve. However, summation of areas of both peaks (5.5 and 11.5
min) resulted in a calibration curve with excellent linearity and coefficient of determina-
tion, R2, of 0.9985. The regression equation obtained is:
y = 40427x + 27319
The bias values of the standard curve were less than 7%, and the standard deviation
values of three replicates were less than 0.5%. The lower limit of quantification, LOQ, of
doxorubicin in blood was 12.38 ± 0.89 ng mL–1 with an RSD of 11.6%. The limit of detec-
tion (LOD) was found to be 3.52 ng mL–1.
A good linearity and correlation coefficient of the calibration curve constructed by
the summation areas of two peaks suggests the interaction of doxorubicin with the blood
components in the presence of AgNO3. This results in a complex with reduced polarity,
eluting in the form of a second peak at 11.5 min. The presence of the second peak was
also confirmed in the whole blood samples of dog, to which doxorubicin was adminis-
tered by intravenous or intraperitoneal route (unpublished data).
Accuracy of the method was determined by subjecting known amounts of doxoru-
bicin to recovery studies in dog blood (n = 6). Table II presents the results obtained. The
concentrations selected for the assay were 75, 150 and 225 ng mL–1 and the percentage
recovery was found to be 96.7 to 100.4%. Precision of the method was ascertained for six
replicate assays at 75, 150 and 225 ng mL–1: RSD ranged from 2.6 to 5.7%.
Results for doxorubicin stability in dog blood samples obtained are shown in Table
III. The percent recovery of doxorubicin under the above storage conditions was found
to be between 95.7 and 100.4%. No appreciable variation in the measured concentrations
in dog blood samples following storage at 28 °C for up to 8 h, and at 5 °C for up to 3
days, indicate the stability of doxorubicin in dog whole blood.
CONCLUSIONS
The proposed HPLC method is simple, rapid and sensitive for the determination of
doxorubicin in dog whole blood. It has been shown to be precise and capable of accu-
rately quantifying the drug. It is concluded that the treatment of whole blood or hae-
molyzed plasma samples containing doxorubicin with AgNO3 results in appearance of
an additional peak along with the parent peak in the chromatogram. Hence, caution has
to be exercised while using AgNO3 for the treatment of whole blood or plasma samples
for the estimation of doxorubicin.
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S A @ E T A K
Brza i osjetljiva HPLC metoda za odre|ivanje doksorubicina
u krvi psa  Artifakt srebrovog nitrata
LAKKIREDDY HARIVARDHAN REDDY, NAGESH MEDA i RAYASA RAMACHANDRA MURTHY
Razvijena je i validirana brza i osjetljiva metoda visokotla~ne teku}inske kromato-
grafije (HPLC) s fluorimetrijskom detekcijom za odre|ivanje doksorubicina u krvi psa.
Nakon obrade uzoraka krvi koji sadr`e doksorubicin s AgNO3 (talo`no sredstvo za pro-
teine), uz osnovni signal (tR = 5,5 min) pojavljuje se dodatni signal u kromatogramu dok-
sorubicina na 11,5 min. Nikakav dodatni signal se ne pojavljuje ako se za talo`enje pro-
teina upotrijebe trikloroctena kiselina ili metanol. Me|utim, u hemoliziranim uzorcima
plazme kojima je dodan doksorubicin nakon obrade sa srebrovim nitratom pojavljuje se
drugi signal. Kalibracijska krivulja s povr{inom ispod signala za samo prvi pik (tR = 5,5
min) nije linearna. Me|utim, suma povr{ina ispod prvog (tR = 5,5 min) i drugog signala
(tR = 11,5 min) daje linearnu zavisnost s korelacijskim koeficijentom R
2 = 0,9985. Pojava
drugog signala mogla bi biti posljedicom interakcije doksorubicina sa stani~nim kom-
ponentama u krvi u prisutnosti AgNO3 te nastajanja kompleksa smanjene polarnosti.
Povr{ina ispod signala na kromatogramu odre|ena na temelju fluorescencijske detekcije
na 480 nm i 560 nm (valne duljine pobu|ivanja, odnosno emisije) upotrebljena je za kvan-
titativnu analizu doksorubicina. Odre|ivanje doksorubicina u krvi psa je jednostavno,
precizno i to~no. U svim eksperimentima, relativna standardna devijacija (RSD) naj~e{}e
je bila < 10%, a izmjerena i teorijska koncentracija razlikovala se za < 10%. Doksorubicin
inkubiran s uzorcima krvi psa bio je stabilan najmanje 3 dana ~uvan na 5 °C, odnosno
najmanje 8 h ~uvan na sobnoj temperaturi (28 °C). Predlo`ena HPLC metoda mogla bi
imati prednosti u odre|ivanju doksorubicina u sustavima za isporuku lijekova ciljano u
krvne stanice i kvantifikaciji ukupne koncentracije doksorubicina u krvi.
Klju~ne rije~i: doksorubicin, krv psa, plazma psa, srebrov nitrat, HPLC
Drug Delivery Research Laboratory, Center of Relevance and Excellence in NDDS, Pharmacy
Department, G.H. Patel Building, M.S. University of Baroda, Vadodara-390002, Gujarat, India
Bioanalytical Division, Sun Pharma Advanced Research Center, Akota Road, Baroda-390020, India
91
L. H. Reddy et al.: Rapid and sensitive HPLC method for the estimation of doxorubicin in dog blood – The silver nitrate artifact, Acta
Pharm. 55 (2005) 81–91.
